---
title: "BioLineRx Ltd. (BLRX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BLRX.US.md"
symbol: "BLRX.US"
name: "BioLineRx Ltd."
industry: "Biotechnology"
datetime: "2026-05-19T10:42:45.880Z"
locales:
  - [en](https://longbridge.com/en/quote/BLRX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BLRX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BLRX.US.md)
---

# BioLineRx Ltd. (BLRX.US)

## Company Overview

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.biolinerx.com](https://www.biolinerx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: D (0.64)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 309 / 387 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -95.92% |  |
| Net Profit YoY | 87.26% |  |
| P/B Ratio | 0.67 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 12162042.82 |  |
| Revenue | 1180000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -7.42% | D |
| Profit Margin | -99.58% | E |
| Gross Margin | 80.51% | A |
| Revenue YoY | -95.92% | E |
| Net Profit YoY | 87.26% | A |
| Total Assets YoY | 5.14% | C |
| Net Assets YoY | 73.43% | A |
| Cash Flow Margin | 687.15% | A |
| OCF YoY | -95.92% | E |
| Turnover | 0.03 | E |
| Gearing Ratio | 42.93% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - BioLineRx Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-95.92%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "87.26%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.67",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "12162042.82",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1180000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-7.42%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-99.58%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "80.51%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-95.92%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "87.26%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "5.14%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "73.43%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "687.15%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-95.92%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.03",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "42.93%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -10.35 | 455/387 | - | - | - |
| PB | 0.67 | 58/387 | 0.86 | 0.74 | 0.64 |
| PS (TTM) | 10.31 | 166/387 | 1.11 | 0.96 | 0.86 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Vaxart (VXRT.US) | A | A | A | C | B | A |
| 05 | Spero Therap (SPRO.US) | A | A | B | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-18T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.79 |
| Highest Target | 23.00 |
| Lowest Target | 12.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BLRX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BLRX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BLRX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BLRX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**